Chinook Therapeutics Debt 2024

Chinook Therapeutics Aktienanalyse

What does Chinook Therapeutics do?

Chinook Therapeutics Inc. is a biotechnology company focused on the discovery, development, and commercialization of novel therapeutics to treat diseases involving inadequate or faulty kidney function, as well as immune and inflammatory mechanisms. The headquarters of Chinook Therapeutics is located in Seattle, Washington, USA. The company was founded in 2019 by a team of experienced executives in the biotechnology industry, including Tom Frohlich, former Vice President at Omeros Corporation, and Eric Dobmeier and Yi Liu, both formerly with Juno Therapeutics. Chinook Therapeutics aims to improve treatment options for patients with kidney diseases by developing novel therapeutics that influence kidney metabolism and the function of immune and inflammatory mechanisms. Chinook's products are intended to have the potential to slow down or stop the progression of kidney diseases and improve patients' lives. Chinook Therapeutics' business model focuses on supporting the discovery and development of potential therapeutics in the earliest stages to optimize the prospects of later commercialization. The company pursues a pipeline-based strategy that includes a variety of development programs with different focuses. The various divisions of Chinook Therapeutics include the following areas: 1. Therapeutic products for kidney diseases Chinook Therapeutics focuses on the discovery and development of therapeutics for kidney diseases targeting various aspects of kidney metabolism. An example of this is the drug candidate BION-1301, an antibody targeting the binding site of APRIL and BAFF on CD40, with the goal of controlling the progression of glomerulonephritis. 2. Immunology and anti-inflammatory therapeutics Chinook Therapeutics is also specialized in the discovery and development of therapeutics targeting the control of immune and inflammation-related diseases. An example of this is the drug candidate CHN-083, a potent inhibitor of the kinase TRPM8, specifically designed for pain relief in inflammatory conditions. 3. Partnerships with other companies Chinook Therapeutics also collaborates closely with other biotechnology companies and research institutions to accelerate the development of therapeutics and enable the commercialization of innovative products. One such partnership is with Arrowhead Pharmaceuticals, whose RNAi technology Chinook can utilize for developing therapeutics for rare diseases as well as kidney and urinary tract disorders. Chinook Therapeutics has established itself as an innovative biotechnology company driving the development of novel therapeutics in the areas of kidney diseases, immunology, and inflammation. The company relies on a pipeline-based strategy and works closely with other companies and research institutions to efficiently bring its developments to the market. Chinook Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Chinook Therapeutics's Debt Structure

Chinook Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Chinook Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Chinook Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Chinook Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Chinook Therapeutics stock

What is the debt of Chinook Therapeutics this year?

Chinook Therapeutics has a debt level of -115.44 USD this year.

What was the debt of Chinook Therapeutics compared to the previous year?

The debt of Chinook Therapeutics has increased by -36.48% compared to the previous year dropped.

What are the consequences of high debt for investors in Chinook Therapeutics?

High debt can pose a risk for investors of Chinook Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Chinook Therapeutics?

Low debt means that Chinook Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Chinook Therapeutics affect the company?

An increase in debt of Chinook Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Chinook Therapeutics affect the company?

A reduction in debt of Chinook Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Chinook Therapeutics?

Some factors that can influence the debt of Chinook Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Chinook Therapeutics so important for investors?

The debts of Chinook Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Chinook Therapeutics take to change the debt?

To change the debt, Chinook Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Chinook Therapeutics pay?

Over the past 12 months, Chinook Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Chinook Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Chinook Therapeutics?

The current dividend yield of Chinook Therapeutics is .

When does Chinook Therapeutics pay dividends?

Chinook Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Chinook Therapeutics?

Chinook Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Chinook Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Chinook Therapeutics located?

Chinook Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Chinook Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Chinook Therapeutics from 11/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/20/2024.

When did Chinook Therapeutics pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of Chinook Therapeutics in the year 2023?

In the year 2023, Chinook Therapeutics distributed 0 USD as dividends.

In which currency does Chinook Therapeutics pay out the dividend?

The dividends of Chinook Therapeutics are distributed in USD.